Company Encyclopedia
View More
name
Enlivex Therapeutics
ENLV.US
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd.
1.946 T
ENLV.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dow Jumps 300 Points; Waldencast Shares Plunge

    U.S. stocks rose with the Dow up 0.65% and NASDAQ up 2.32%. Waldencast shares fell 12% after Q2 results. Enlivex Therapeutics surged 48% following a private placement announcement. Commodities saw slight increases, with oil up 0.1% and gold up 0.2%. The Dallas Fed's business activity index for Texas manufacturing dropped to -10.4 in November.

    fidelity·
    US
    WALD
    -0.82%
    US
    ENLV
    +6.42%
    fidelity·
    US
    WALD
    -0.82%
    US
    ENLV
    +6.42%

    Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors | ENLV Stock News

    Enlivex Therapeutics Ltd. has appointed former Italian Prime Minister Matteo Renzi to its Board of Directors, effective November 24, 2025. The company also announced a $212 million private placement to fund a new digital asset treasury strategy using RAIN tokens. Enlivex aims to integrate blockchain technology into its operations while continuing its focus on developing therapies for osteoarthritis. The appointment of Renzi is expected to enhance shareholder value and align with the company's strategic vision for innovation and long-term growth.

    StockTitan·
    US
    ENLV
    +6.42%
    StockTitan·
    US
    ENLV
    +6.42%

    Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

    - Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation.

    GlobeNewswire·
    US
    ENLV
    +6.42%
    GlobeNewswire·
    US
    ENLV
    +6.42%

    Enlivex Taps Matteo Renzi, Bets Big on Prediction Markets

    Enlivex Therapeutics, an Israeli biotech firm, is diversifying by raising $212 million in a PIPE financing round to adopt a treasury strategy focused on the RAIN prediction markets token. This move marks a convergence of biotech funding and decentralized finance. The company plans to use the funds to accumulate RAIN tokens, signaling institutional interest in prediction markets. Former Italian Prime Minister Matteo Renzi joins Enlivex's Board, adding political visibility to this strategy. The approach poses a dual challenge of advancing medical trials while engaging in speculative DeFi investments.

    StartupHub·
    US
    ENLV
    +6.42%
    StartupHub·
    US
    ENLV
    +6.42%

    Enlivex Therapeutics Raises $212 Million in Private Placement

    Enlivex Therapeutics Ltd. announced a $212 million private placement through the sale of 212 million shares at $1.00 each, an 11.5% premium over the previous closing price. The funds will support a new digital asset treasury strategy and the development of Allocetra™ therapy for knee osteoarthritis. The transaction is expected to close by November 25, 2025, pending customary conditions.

    Reuters·
    US
    ENLV
    +6.42%
    Reuters·
    US
    ENLV
    +6.42%
    © 2025 Longbridge｜Disclaimer